I compiled a summary of US sales for DAYBUE and SKYCLARYS, same launch time, DAYBUE has been performing better than SKYCLARYS in sales in US.
Given SKYCLARYS/Reata was acquired in 2023 for US$7.3B, NEU is still valued at US$1.05B with net cash around $320m including US$50m milestone payment to receive this quarter less accrued income tax.
According to Acadia sale guidance, NEU will receive royalties for 2025 DAYBUE sales, royalties will be around $64m to $69m, then likely another milestone payment for first Europe sale of US$35m/$55m, and bank interest income around $16m, NEU 2025 income are likely to be around $135m to $140m, on top of existing net cash position of around $320m, based on my estimates.
DYOR & ALL IMO.
![]()
- Forums
- ASX - By Stock
- NEU
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.28%
!
$12.54

Acadia, page-1357
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 665 | $12.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.55 | 235 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 665 | 12.500 |
1 | 1537 | 12.470 |
1 | 1537 | 12.450 |
2 | 2037 | 12.420 |
1 | 42 | 12.400 |
Price($) | Vol. | No. |
---|---|---|
12.600 | 899 | 1 |
12.690 | 1537 | 1 |
12.720 | 2537 | 2 |
12.730 | 1010 | 1 |
12.750 | 1537 | 1 |
Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |